We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+32.45%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$260M
AUM Growth
-$4.29M
Cap. Flow
-$19.9M
Cap. Flow %
-7.65%
Top 10 Hldgs %
66.62%
Holding
31
New
–
Increased
–
Reduced
3
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$10.4M
2
ANAB icon
AnaptysBio
ANAB
+$6.65M
3
CDTX
Cidara Therapeutics
CDTX
+$1.22M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$806K
5
TRDA icon
Entrada Therapeutics
TRDA
+$805K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLYB icon
26
Rallybio
RLYB
$84.5M
$1.23M 0.47%
453,841
– –
ADVM
27
DELISTED
Adverum Biotechnologies
ADVM
$1.16M 0.45%
541,666
– –
ZNTL icon
28
Zentalis Pharmaceuticals
ZNTL
$337M
$568K 0.22%
490,000
– –
MRSN
29
DELISTED
Mersana Therapeutics
MRSN
$386K 0.15%
52,200
– –
ANAB icon
30
AnaptysBio
ANAB
$1.58B
– –
-357,733
Closed -$6.65M
CDTX
31
DELISTED
Cidara Therapeutics
CDTX
– –
-56,725
Closed -$1.22M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2025 Portfolio in Review

As of Q2 2025, 5AM Venture Management held 31 positions worth $260M, down 1.6% from $264M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

5AM Venture Management withdrew a net $19.9M in Q2 2025, closing 2 positions and reducing 3 holdings. Its most notable exit was AnaptysBio, an estimated $6.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's biggest Q2 2025 reduction was Enliven Therapeutics, cutting an estimated $10.4M.
  • 5AM Venture Management fully exited AnaptysBio in Q2 2025, selling an estimated $6.65M.
  • 5AM Venture Management's ten largest holdings make up 67% of its $260M portfolio in Q2 2025.
  • 5AM Venture Management opened 0 new positions and closed 2 in Q2 2025.
  • 5AM Venture Management's portfolio value fell 1.6% quarter-over-quarter to $260M.

Based on 5AM Venture Management's 13F filing for Q2 2025, filed 14 Aug 2025.